This heterogeneity poses challenges in screening and treatment of PCa [2].The initial evaluation typically begins with a digital rectal examination (DRE) and a prostate-specific antigen (PSA) test [4]. The gene discussed is KLK3; the disease is posterior cortical atrophy.